Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide for Dumping Syndrome (Phase II, SC then LAR)
DRKS00004215Phase 2Recruiting
- Sponsor
- Novartis
- Start
- May 2015
- Modality
- Small Molecules, Peptides
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of pasireotide LAR in dumping syndrome and postgastrectomy syndrome (PGS), sponsored by Novartis. Primary endpoints: Preliminary efficacy of pasireotide on dumping syndrome, Safety of pasireotide and 1 more. Started May 2015; status: recruiting.
02
Drugs
pasireotide LAR
03
Conditions
dumping syndromepostgastrectomy syndrome (PGS)
Beyond the preview
Go deeper on DRKS00004215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00004215.